Thromboxane and the thromboxane receptor in cardiovascular disease

Clinical Lipidology

Volumn 5, Issue 2, 2010, Pages 209-219

  Smyth, Emer M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Aspirin; Cardiovascular disease; Cyclooxygenase; Platelets; Thromboxane A 2

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; ISOPROSTANE DERIVATIVE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTAGLANDIN SYNTHASE INHIBITOR; TERUTROBAN; THROMBOXANE A2; THROMBOXANE RECEPTOR; THROMBOXANE RECEPTOR BLOCKING AGENT; THROMBOXANE SYNTHASE; THROMBOXANE SYNTHASE INHIBITOR;

ARACHIDONIC ACID METABOLISM; ATHEROSCLEROSIS; BLEEDING; BRAIN ISCHEMIA; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; DRUG TOLERABILITY; DRUG USE; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW; THROMBOSIS; THROMBOSIS PREVENTION;

EID: 77950262861     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/CLP.10.11     Document Type: Review

References (120)

1. Smyth EM, FitzGerald GA: Prostaglandin mediators. In Handbook of Cell Signaling. Second Edition. Bradshaw RA, Dennis EA (Eds). Academic Press, UK 1219-1228 (2009).
2. Hirata M, Hayashi Y, Ushikubi F et al.: Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature 349, 617-620 (1991).
3. Catella F, Healy D, Lawson JA et al.: 11-dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Proc. Natl Acad. Sci. USA 83, 5861-5865 (1986).
4. Fitzgerald DJ, Roy L, Catella F et al.: Platelet activation in unstable coronary disease. N.Engl. J. Med.315, 983-989 (1986).
5. McAdam BF, Mardini IA, Habib A et al.: Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. J.Clin. Invest. 105, 1473-1482 (2000).
6. Fitzgerald DJ, Rocki W, Murray R et al.: Thromboxane A2 synthesis in pregnancy-induced hypertension. Lancet 335, 751-754 (1990).
7. Lupinetti MD, Sheller JR, Catella F et al.: Thromboxane biosynthesis in allergen-induced bronchospasm. Evidence for platelet activation. Am. Rev. Respir. Dis. 140, 932-935 (1989).
8. Reilly IA, Roy L, Fitzgerald GA: Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon. Br.Med. J. (Clin. Res. Ed.) 292, 1037-1039 (1986).
9. Reilly IA, Doran JB, Smith B et al.: Increased thromboxane biosynthesis in a human preparation of platelet activation: biochemical and functional consequences of selective inhibition of thromboxane synthase. Circulation 73, 1300-1309 (1986).
10. Reilly MP, Delanty N, Roy L et al.: Increased formation of the isoprostanes IPF2a-I and 8-epi-prostaglandin F2a in acute coronary angioplasty: evidence for oxidant stress during coronary reperfusion in humans. Circulation 96, 3314-3320 (1997).
11. Reilly MP, Pratico D, Delanty N et al.: Increased formation of distinct F2 isoprostanes in hypercholesterolemia. Circulation 98, 2822-2828 (1998).
12. Audoly LP, Rocca B, Fabre JE et al.: Cardiovascular responses to the isoprostanes iPF(2a)-III and iPE(2)-III are mediated via the thromboxane A2 receptor in vivo. Circulation 101, 2833-2840 (2000).
13. Katugampola SD, Davenport AP: Thromboxane receptor density is increased in human cardiovascular disease with evidence for inhibition at therapeutic concentrations by the AT1 receptor antagonist losartan. Br. J. Pharmacol. 134, 1385-1392 (2001).
14. Cheng Y, Austin SC, Rocca B et al.: Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 296, 539-541 (2002).
15. Kobayashi T, Tahara Y, Matsumoto M et al.: Roles of thromboxane A2 and prostacyclin in the development of atherosclerosis in ApoE-deficient mice. J. Clin. Invest. 114, 784-794 (2004).
16. Xiao CY, Hara A, Yuhki K et al.: Roles of prostaglandin I2 and thromboxane A2 in cardiac ischemia-reperfusion injury: a study using mice lacking their respective receptors. Circulation 104, 2210-2215 (2001).
17. Cayatte AJ, Du Y, Oliver-Krasinski J et al.: The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in ApoE-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 20, 1724-1728 (2000).
18. Hirata T, Kakizuka A, Ushikubi F et al.: Arg60 to Leu mutation of the human thromboxane A2 receptor in a dominantly inherited bleeding disorder. J. Clin. Invest. 94, 1662-1667 (1994).
19. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. Br. J. Med. 308, 81-106 (1994).
20. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324, 71-86 (2002).
21. Sanmuganathan PS, Ghahramani P, Jackson PR et al.: Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 85, 265-271 (2001).
22. Ridker PM, Cook NR, Lee IM et al.: A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N. Engl. J. Med.352, 1293-1304 (2005).
23. Ding X, Murray PA: Cellular mechanisms of thromboxane A2-mediated contraction in pulmonary veins. Am. J. Physiol. Lung Cell. Mol. Physiol. 289, L825-L833 (2005).
24. Winn R, Harlan J, Nadir B et al.: Thromboxane A2 mediates lung vasoconstriction but not permeability after endotoxin. J. Clin. Invest. 72, 911-918 (1983).
25. Yamamoto K, Ebina S, Nakanishi H et al.: Thromboxane A2 receptor-mediated signal transduction in rabbit aortic smooth muscle cells. Gen. Pharmacol. 26, 1489-1498 (1995).
26. Ishizuka T, Kawakami M, Hidaka T et al.: Stimulation with thromboxane A2 (TXA2) receptor agonist enhances ICAM-1, VCAM-1 or ELAM-1 expression by human vascular endothelial cells. Clin. Exp. Immunol. 112, 464-470 (1998).
27. Nie D, Lamberti M, Zacharek A et al.: Thromboxane A2 regulation of endothelial cell migration, angiogenesis, and tumor metastasis. Biochem. Biophys. Res. Commun.267, 245-251 (2000).
28. Jones DA, Benjamin CW, Linseman DA: Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. Mol. Pharmacol.48, 890-896 (1995).
29. Nagata T, Uehara Y, Numabe A et al.: Regulatory effect of thromboxane A2 on proliferation of vascular smooth muscle cells from rats. Am. J. Physiol. 263, H1331-H1338 (1992).
30. Sachinidis A, Flesch M, Ko Y et al.: Thromboxane A2 and vascular smooth muscle cell proliferation. Hypertension 26, 771-780 (1995).
31. Ali S, Davis MG, Becker MW et al.: Thromboxane A2 stimulates vascular smooth muscle hypertrophy by up-regulating the synthesis and release of endogenous basic fibroblast growth factor. J. Biol. Chem. 268, 17397-17403 (1993).
32. Craven PA, Studer RK, DeRubertis FR: Thromboxane/prostaglandin endoperoxide-induced hypertrophy of rat vascular smooth muscle cells is signaled by protein kinase C-dependent increases in transforming growth factor-b. Hypertension 28, 169-176 (1996).
33. Simmons DL, Botting RM, Hla T: Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol. Rev. 56, 387-437 (2004).
34. Smyth EM, Grosser T, Wang M et al.: Prostanoids in health and disease. J. Lipid Res. 50(Suppl.), S423-S428 (2009).
35. Habib A, Vezza R, Creminon C et al.: Rapid, agonist-dependent phosphorylation in vivo of human thromboxane receptor isoforms. Minimal involvement of protein kinase C. J.Biol. Chem. 272, 7191-7200 (1997).
36. Parent JL, Labrecque P, Orsini MJ et al.: Internalization of the TXA2 receptor a and b isoforms. Role of the differentially spliced cooh terminus in agonist-promoted receptor internalization. J. Biol. Chem. 274, 8941-8948 (1999).
37. Sasaki M, Sukegawa J, Miyosawa K et al.: Low expression of cell-surface thromboxane A2 receptor b-isoform through the negative regulation of its membrane traffic by proteasomes. Prostaglandins Other Lipid Mediat. 83, 237-249 (2007).
38. Pratico D, Smyth EM, Violi F et al.: Local amplification of platelet function by 8-epi prostaglandin F2a is not mediated by thromboxane receptor isoforms. J. Biol. Chem. 271, 14916-14924 (1996).
39. Wilson SJ, McGinley K, Huang AJ et al.: Heterodimerization of the a and b isoforms of the human thromboxane receptor enhances isoprostane signaling. Biochem. Biophys. Res. Commun.352, 397-403 (2007).
40. Montuschi P, Barnes PJ, Roberts LJ 2nd: Isoprostanes: markers and mediators of oxidative stress. FASEB J. 18, 1791 - 1800 (2004).
41. Egan KM, Wang M, Lucitt MB et al.: Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 111, 334-342 (2005).
42. Wilson SJ, O'Connell C, Lesher AM et al.: Activation dependent stabilization of the human thromboxane receptor: role of reactive oxygen species. J. Lipid Res. 50(6), 1047-1056 (2009).
43. Valentin F, Field MC, Tippins JR: The mechanism of oxidative stress stabilization of the thromboxane receptor in COS-7 cells. J.Biol. Chem. 279, 8316-8324 (2004).
44. Francois H, Athirakul K, Mao L et al.: Role for thromboxane receptors in angiotensin-II-induced hypertension. Hypertension 43, 364-369 (2004).
45. Michel F, Silvestre JS, Waeckel L et al.: Thromboxane A2/prostaglandin H2 receptor activation mediates angiotensin II-induced postischemic neovascularization. Arterioscler. Thromb. Vasc. Biol. 26, 488-493 (2006).
46. Pettipher R, Hansel TT, Armer R: Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nat. Rev. Drug Discov.6, 313-325 (2007).
47. Liston TE, Roberts LJ 2nd: Transformation of prostaglandin D2 to 9a, 11b-(15S)-trihydroxyprosta-(5Z,13E)-dien-1-oic acid (9a, 11b-prostaglandin F2): a unique biologically active prostaglandin produced enzymatically in vivo in humans. Proc. Natl Acad. Sci. USA 82, 6030-6034 (1985).
48. Bohm E, Sturm GJ, Weiglhofer I et al.: 11-Dehydro-thromboxane B2, a stable thromboxane metabolite, is a full agonist of chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2) in human eosinophils and basophils. J. Biol. Chem. 279, 7663-7670 (2004).
49. Mollace V, Muscoli C, Masini E et al.: Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors. Pharmacol. Rev. 57, 217-252 (2005).
50. Salvemini D, Misko TP, Masferrer JL et al.: Nitric oxide activates cyclooxygenase enzymes. Proc. Natl Acad. Sci. USA 90, 7240-7244 (1993).
51. Marnett LJ, Wright TL, Crews BC et al.: Regulation of prostaglandin biosynthesis by nitric oxide is revealed by targeted deletion of inducible nitric-oxide synthase. J. Biol. Chem. 275, 13427-13430 (2000).
52. Salvemini D, Currie MG, Mollace V: Nitric oxide-mediated cyclooxygenase activation. A key event in the antiplatelet effects of nitrovasodilators. J. Clin. Invest. 97, 2562-2568 (1996).
53. Minghetti L, Polazzi E, Nicolini A et al.: Interferon-g and nitric oxide down-regulate lipopolysaccharide-induced prostanoid production in cultured rat microglial cells by inhibiting cyclooxygenase-2 expression. J.Neurochem. 66, 1963-1970 (1996).
54. Doni MG, Whittle BJ, Palmer RM et al.: Actions of nitric oxide on the release of prostacyclin from bovine endothelial cells in culture. Eur. J. Pharmacol. 151, 19-25 (1988).
55. Schildknecht S, van der Loo B, Weber K et al.: Endogenous peroxynitrite modulates PGHS-1-dependent thromboxane A2 formation and aggregation in human platelets. Free Radic. Biol. Med.45, 512-520 (2008).
56. Marjanovic JA, Li Z, Stojanovic A et al.: Stimulatory roles of nitric-oxide synthase 3 and guanylyl cyclase in platelet activation. J.Biol. Chem. 280, 37430-37438 (2005).
57. Iafrati MD, Vitseva O, Tanriverdi K et al.: Compensatory mechanisms influence hemostasis in setting of eNOS deficiency. Am.J. Physiol. Heart Circ. Physiol. 288, H1627-H1632 (2005).
58. Li Z, Xi X, Gu M et al.: A stimulatory role for cGMP-dependent protein kinase in platelet activation. Cell112, 77-86 (2003).
59. Houston DS, Shepherd JT, Vanhoutte PM: Aggregating human platelets cause direct contraction and endothelium-dependent relaxation of isolated canine coronary arteries. Role of serotonin, thromboxane A2, and adenine nucleotides. J. Clin. Invest. 78, 539-544 (1986).
60. Chen L, Salafranca MN, Mehta JL: Cyclooxygenase inhibition decreases nitric oxide synthase activity in human platelets. Am. J. Physiol. 273, H1854-H1859 (1997).
61. Gleim S, Kasza Z, Martin K et al.: Prostacyclin receptor/thromboxane receptor interactions and cellular responses in human atherothrombotic disease. Curr. Atheroscler. Rep.11, 227-235 (2009).
62. Rudic RD, Brinster D, Cheng Y et al.: COX-2-derived prostacyclin modulates vascular remodeling. Circ. Res. 96, 1240-1247 (2005).
63. Egan KM, Lawson JA, Fries S et al.: COX-2-derived prostacyclin confers atheroprotection on female mice. Science 306, 1954-1957 (2004).
64. Wikstrom K, Kavanagh DJ, Reid HM et al.: Differential regulation of RhoA-mediated signaling by the TPa and TPb isoforms of the human thromboxane A2 receptor: independent modulation of TPa signaling by prostacyclin and nitric oxide. Cell Signal. 20, 1497-1512 (2008).
65. Wilson SJ, Dowling JK, Zhao L et al.: Regulation of thromboxane receptor trafficking through the prostacyclin receptor in vascular smooth muscle cells: role of receptor heterodimerization. Arterioscler. Thromb. Vasc. Biol. 27, 290-296 (2007).
66. Wilson SJ, Roche AM, Kostetskaia E et al.: Dimerization of the human receptors for prostacyclin and thromboxane facilitates thromboxane receptor-mediated cAMP generation. J. Biol. Chem. 279, 53036-53047 (2004).
67. Grosser T, Fries S, Fitzgerald GA: Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest. 116, 4-15 (2006).
68. Yu Y, Ricciotti E, Grosser T et al.: The translational therapeutics of prostaglandin inhibition in atherothrombosis. J. Thromb. Haemost. 7(Suppl. 1), 222-226 (2009).
69. Francois H, Makhanova N, Ruiz P et al.: A role for the thromboxane receptor in L-NAME hypertension. Am. J. Physiol. Renal Physiol. 295, F1096-F1102 (2008).
70. Cyrus T, Ding T, Pratico D: Expression of thromboxane synthase, prostacyclin synthase and thromboxane receptor in atherosclerotic lesions: correlation with plaque composition. Atherosclerosis. 208(2), 376-381 (2010).
71. Zhang Z, Vezza R, Plappert T et al.: COX-2-dependent cardiac failure in Gh/tTG transgenic mice. Circ. Res. 92, 1153-1161 (2003).
72. Xu S, Jiang B, Maitland KA et al.: The thromboxane receptor antagonist s18886 attenuates renal oxidant stress and proteinuria in diabetic apolipoprotein E-deficient mice. Diabetes 55, 110-119 (2006).
73. Ashton AW, Ware JA: Thromboxane A2 receptor signaling inhibits vascular endothelial growth factor-induced endothelial cell differentiation and migration. Circ. Res. 95, 372-379 (2004).
74. Ashton AW, Cheng Y, Helisch A et al.: Thromboxane A2 receptor agonists antagonize the proangiogenic effects of fibroblast growth factor-2: role of receptor internalization, thrombospondin-1, and avb3. Circ. Res. 94, 735-742 (2004).
75. Benndorf RA, Schwedhelm E, Gnann A et al.: Isoprostanes inhibit vascular endothelial growth factor-induced endothelial cell migration, tube formation, and cardiac vessel sprouting in vitro, as well as angiogenesis in vivo via activation of the thromboxane A2 receptor: a potential link between oxidative stress and impaired angiogenesis. Circ. Res. 103, 1037-1046 (2008).
76. Daniel TO, Liu H, Morrow JD et al.: Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res. 59, 4574-4577 (1999).
77. Wei J, Yan W, Li X et al.: Thromboxane receptor a mediates tumor growth and angiogenesis via induction of vascular endothelial growth factor expression in human lung cancer cells. Lung Cancer, DOI: doi:10.1016/j.lungcan.2009.09.009 (2009) (Epub ahead of print).
78. Rocca B, Loeb AL, Strauss JF 3rd et al.: Directed vascular expression of the thromboxane A2 receptor results in intrauterine growth retardation. Nat. Med. 6, 219-221 (2000).
79. Solomon SD, McMurray JJ, Pfeffer MA et al.: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med.352, 1071-1080 (2005).
80. Psaty BM, Kronmal RA: Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. JAMA 299, 1813-1817 (2008).
81. Nussmeier NA, Whelton AA, Brown MT et al.: Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N. Engl. J. Med.352, 1081-1091 (2005).
82. Ott E, Nussmeier NA, Duke PC et al.: Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J. Thorac. Cardiovasc. Surg. 125, 1481-1492 (2003).
83. Arber N, Eagle CJ, Spicak J et al.: Celecoxib for the prevention of colorectal adenomatous polyps. N. Engl. J. Med.355, 885-895 (2006).
84. Bresalier RS, Sandler RS, Quan H et al.: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med.352, 1092-1102 (2005).
85. Patrono C, Garcia Rodriguez LA, Landolfi R et al.: Low-dose aspirin for the prevention of atherothrombosis. N. Engl. J. Med.353, 2373-2383 (2005).
86. Cipollone F, Patrignani P, Greco A et al.: Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation 96, 1109-1116 (1997).
87. Patrono C: The PGH-synthase system and isozyme-selective inhibition. J. Cardiovasc. Pharmacol. 47(Suppl. 1), S1-S6 (2006).
88. Roth GJ, Stanford N, Majerus PW: Acetylation of prostaglandin synthase by aspirin. Proc. Natl Acad. Sci. USA 72, 3073-3076 (1975).
89. DeWitt DL, el-Harith EA, Kraemer SA et al.: The aspirin and heme-binding sites of ovine and murine prostaglandin endoperoxide synthases. J. Biol. Chem. 265, 5192-5198 (1990).
90. Patrono C, Coller B, Dalen JE et al.: Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 119, S39-S63 (2001).
91. Garcia Rodriguez LA, Cattaruzzi C, Troncon MG et al.: Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch. Intern. Med. 158, 33-39 (1998).
92. Patrono C, Rocca B: Aspirin: promise and resistance in the new millennium. Arterioscler. Thromb. Vasc. Biol. 28, S25-S32 (2008).
93. Catella-Lawson F, Reilly MP, Kapoor SC et al.: Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med.345, 1809-1817 (2001).
94. Capone ML, Sciulli MG, Tacconelli S et al.: Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J.Am. Coll. Cardiol. 45, 1295-1301 (2005).
95. Hermann M: Cardiovascular risk associated with nonsteroidal anti-inflammatory drugs. Curr. Rheumatol. Rep. 11, 31-35 (2009).
96. Fitzgerald DJ, Fragetta J, FitzGerald GA: Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis. J. Clin. Invest. 82, 1708-1713 (1988).
97. Morio H, Hirai A, Terano T et al.: Effect of the infusion of OKY-046, a thromboxane A2 synthase inhibitor, on urinary metabolites of prostacyclin and thromboxane A2 in healthy human subjects. Thromb. Haemost. 69, 276-281 (1993).
98. Wang M, Lee E, Song W et al.: Microsomal prostaglandin E synthase-1 deletion suppresses oxidative stress and angiotensin II-induced abdominal aortic aneurysm formation. Circulation 117(10), 1302-1309 (2008).
99. Wang M, Zukas AM, Hui Y et al.: Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proc. Natl Acad. Sci. USA 103, 14507-14512 (2006).
100. Cipollone F, Cicolini G, Bucci M: Cyclooxygenase and prostaglandin synthases in atherosclerosis: recent insights and future perspectives. Pharmacol. Ther. 118, 161-180 (2008).
101. Cyrus T, Yao Y, Ding T et al.: Thromboxane receptor blockade improves the antiatherogenic effect of thromboxane A2 suppression in LDLR KO mice. Blood 109, 3291-3296 (2007).
102. Cyrus T, Yao Y, Ding T et al.: A novel thromboxane receptor antagonist and synthase inhibitor, BM-573, reduces development and progression of atherosclerosis in LDL receptor deficient mice. Eur. J. Pharmacol. 561, 105-111 (2007).
103. Smyth SS, Woulfe DS, Weitz JI et al.: G-protein-coupled receptors as signaling targets for antiplatelet therapy. Arterioscler. Thromb. Vasc. Biol. 29, 449-457 (2009).
104. Belch J, MacCuish A, Campbell I et al.: The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 337, A1840 (2008).
105. Berger JS, Krantz MJ, Kittelson JM et al.: Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA 301, 1909-1919 (2009).
106. Celestini A, Violi F: A review of picotamide in the reduction of cardiovascular events in diabetic patients. Vasc. Health Risk Manag. 3, 93-98 (2007).
107. Vilahur G, Casani L, Badimon L: A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis. Thromb. Haemost. 98, 662-669 (2007).
108. Bal Dit Sollier C, Crassard I, Simoneau G et al.: Effect of the thromboxane prostaglandin receptor antagonist terutroban on arterial thrombogenesis after repeated administration in patients treated for the prevention of ischemic stroke. Cerebrovasc.Dis. 28, 505-513 (2009).
109. Chamorro A: TP receptor antagonism: a new concept in atherothrombosis and stroke prevention. Cerebrovasc. Dis. 27(Suppl. 3), 20-27 (2009).
110. Belhassen L, Pelle G, Dubois-Rande JL et al.: Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin. J. Am. Coll. Cardiol. 41, 1198-1204 (2003).
111. Hennerici MG: Rationale and design of the Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) Study. Cerebrovasc. Dis. 27(Suppl. 3), 28-32 (2009).
112. Moussa O, Ashton AW, Fraig M et al.: Novel role of thromboxane receptors b isoform in bladder cancer pathogenesis. Cancer Res. 68, 4097-4104 (2008).
113. Yan W, Ding Y, Tai HH: 14-13-3z interacts with human thromboxane receptors and is involved in the agonist-induced activation of the extracellular-signal-regulated kinase. Biochem. Pharmacol. 71, 624-633 (2006).
114. Parent A, Laroche G, Hamelin E et al.: RACK1 regulates the cell surface expression of the G protein-coupled receptor for thromboxane A2. Traffic. 9, 394-407 (2008).
115. Giguere P, Turcotte ME, Hamelin E et al.: Peroxiredoxin-4 interacts with and regulates the thromboxane A2 receptor. FEBS Lett. 581, 3863-3868 (2007).
116. Lemaitre RN, Rice K, Marciante K et al.: Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke. Atherosclerosis 204, E58-E63 (2009).
117. Lee CR, North KE, Bray MS et al.: Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study. Clin. Pharmacol. Ther. 83, 52-60 (2008).
118. Sellers MM, Stallone JN: Sympathy for the devil: the role of thromboxane in the regulation of vascular tone and blood pressure. Am. J. Physiol. Heart Circ. Physiol. 294, H1978-H1986 (2008).
119. Rochdi MD, Laroche G, Dupre E et al.: Nm23-H2 interacts with a G protein-coupled receptor to regulate its endocytosis through an Rac1-dependent mechanism. J.Biol. Chem. 279, 18981-18989 (2004).
120. Theriault C, Rochdi MD, Parent JL: Role of the Rab11-associated intracellular pool of receptors formed by constitutive endocytosis of the b isoform of the thromboxane A2 receptor (TPb). Biochemistry 43, 5600-5607 (2004).